Mitsuhiro Kamimura

Tachikawa, JP 
Tachikawa, JP 

Overview

Mitsuhiro Kamimura practices practicing medicine in Tachikawa, Japan.

Their clinical expertise encompasses Asthma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Allergic Rhinitis.

They are actively involved in clinical research, co-authoring 28 peer reviewed articles and participating in 2 clinical trials.

Locations

Tachikawa, Japan
Other Locations
Tokyo, Japan
Japan
Kasugai, 4870013, Japan
Midori, 1900014, Japan
Isa, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: May 18, 2026
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Single Arm, Multi-center Study to Assess the Long-term Real-world Safety and Effectiveness of Nucala in EGPA Patients Who Have Already Used Nucala for at Least 96 Weeks in Japan
A Single Arm, Multi-center Study to Assess the Long-term Real-world Safety and Effectiveness of Nucala in EGPA Patients Who Have Already Used Nucala for at Least 96 Weeks in Japan
Enrollment Status: Completed
Publish Date: September 19, 2024
View 1 Less Clinical Trial

28 Total Publications

A comparative analysis of the clinical and genomic characteristics of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus in Korea and Japan.
A comparative analysis of the clinical and genomic characteristics of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus in Korea and Japan.
Journal: Microbiology spectrum
Published: July 21, 2026

Frequently Asked Questions about Mitsuhiro Kamimura

Is Mitsuhiro Kamimura a top-rated expert for Asthma?

MediFind is an objective health platform that identifies experts based on real-world data. Mitsuhiro Kamimura is classified as an Experienced expert for Asthma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mitsuhiro Kamimura participate in research or clinical trials?

Yes. Mitsuhiro Kamimura has published 28 articles and abstracts on conditions like Asthma. You can view a list of Mitsuhiro Kamimura's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kamimura's expertise for a condition
ConditionClose
        View All 16 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile